Clinical Trial Update: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of ADCT-602 for recurrent or refractory B-cell acute lymphoblastic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• ADCT-602

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1, Phase 2 | Status: TERMINATED